<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43378">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696825</url>
  </required_header>
  <id_info>
    <org_study_id>2012-182</org_study_id>
    <nct_id>NCT01696825</nct_id>
  </id_info>
  <brief_title>Comparison of Absorption of Vaginal Diazepam Using Different Delivery Systems</brief_title>
  <official_title>COMPARISON OF ABSORPTION OF VAGINAL DIAZEPAM USING DIFFERENT DELIVERY SYSTEMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jason Gilleran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which of three delivery systems of vaginal
      diazepam have the best systemic absorption, measured by serum diazepam levels.  The three
      delivery systems are: moistened tablet, suppository or cream.  Additionally the study will
      compare the side effects and absorption of vaginal diazepam with oral diazepam.  Vaginal
      diazepam is used off-label vaginally to relax pelvic floor muscles and reduce pelvic pain
      caused from pelvic floor dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Serum diazepam levels measured over time</measure>
    <time_frame>Baseline then 2 hours, 4 hours and 8 hours post-medication administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects observed with each of three types of vaginal diazepam</measure>
    <time_frame>Baseline and 2 hours, 4 hours and 8 hours post medication administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Metabolism, Drug</condition>
  <arm_group>
    <arm_group_label>Diazepam Tablet, 5 mg, Vaginal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diazepam Suppository, 5 mg, Vaginal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diazepam Cream, 5 mg, Vaginal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diazepam Tablet, 5 Mg, Oral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam tablet, 5 mg, vaginal</intervention_name>
    <description>Diazepam tablet, 5 mg, moistened and inserted vaginally</description>
    <arm_group_label>Diazepam Tablet, 5 mg, Vaginal</arm_group_label>
    <arm_group_label>Diazepam Tablet, 5 Mg, Oral</arm_group_label>
    <other_name>Valium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam Suppository, 5 mg, vaginal</intervention_name>
    <description>Compounded diazepam 5 mg suppository administered vaginally</description>
    <arm_group_label>Diazepam Suppository, 5 mg, Vaginal</arm_group_label>
    <arm_group_label>Diazepam Tablet, 5 Mg, Oral</arm_group_label>
    <other_name>Valium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam Cream, 5 mg, Vaginal</intervention_name>
    <description>Compounded diazepam cream, 5 mg, inserted vaginally</description>
    <arm_group_label>Diazepam Cream, 5 mg, Vaginal</arm_group_label>
    <arm_group_label>Diazepam Tablet, 5 Mg, Oral</arm_group_label>
    <other_name>Valium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide informed consent

          -  Premenopausal women &gt; age 18

          -  Able to provide urine and serum samples during the time period

        Exclusion Criteria:

          -  Current use of benzodiazepines in any form.  If history of benzodiazepine use, must
             not have taken for one week prior to study screening and enrollment

          -  Pregnancy

          -  Concomitant use of any narcotic drug, ethanol, or any illicit drug use during the
             study period that could be deemed unsafe in combination with benzodiazepine
             medication use as judged by the investigators.

          -  Any evidence of vaginitis on wet mount slide

          -  Postmenopausal

          -  Subject with any other vaginal epithelial disorder that could affect absorption of
             medication as deemed by the investigators.

          -  Any indication/condition/medication that the investigators identify as
             contraindicated in conjunction with diazepam.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Gilleran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Dove-Medows, CNM, MSN,</last_name>
    <phone>248-898-1259</phone>
    <email>Emily.dove-medows@beaumont.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Carrico, WHNP</last_name>
    <phone>248-898-0898</phone>
    <email>dcarrico@beaumont.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Women's Urology Center, William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Dove-Medows, RN, MSN</last_name>
      <phone>248-898-1259</phone>
      <email>Emily.Dove-medows@beaumont.edu</email>
    </contact>
    <contact_backup>
      <last_name>Donna Carrico, WHNP</last_name>
      <phone>248-898-0898</phone>
      <email>dcarrico@beaumont.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Jason Gilleran</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
